CTO Realty Growth is trading at a forward price-to-funds-from-operations (P/FFO) ratio of 9.7x, below its historical average of 12.1x, offering investors a compelling value and high yield. The company shows strong operational momentum with 18% year-over-year core FFO per share growth and 10% same-property net operating income growth, supported by robust leasing spreads. Its disciplined capital recycling, lease pipeline, and development projects are expected to sustain future growth in FFO and NOI. Both common and preferred shares are rated 'Buy,' with preferred shares yielding 8.2% and trading at a 22% discount to par, making CTO an attractive option for income-focused investors.
CTO Realty Growth offers a compelling value proposition with an 8.2% yield and a 22% discount to par on preferred shares. For readers following Real Estate sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:12 WIB: out of 47 priced US Real Estate stocks, 20 rose and 12 fell. Essex Property Trust (ESS) traded at USD 267.74 with a -0.63% change, CareTrust REIT (CTRE) at USD 36.77 with +0.60%, and UDR Inc. (UDR) at USD 34.29 with +0.51%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
